E-Newsletter - January 2022
Spotlight on Alliance Committees
introducing new alliance leukemia committee co-chairs
Wendy Stock, MD, and Geoffrey L. Uy, MD, have been appointed Co-Chairs of the Alliance Leukemia Committee, effective December 2021. Drs. Stock and Uy replace Richard M. Stone, MD, a Professor of Medicine at Harvard Medical School and Clinical Director of the Adult Leukemia Program at Dana-Farber Cancer Institute, who retired as Committee Chair after 10 years of distinguished service in November 2021.
Dr. Stock is the Anjuli Seth Nayak Professor in Leukemia at the University of Chicago and co-leader of the University of Chicago Cancer Research Center’s Program in Hematopoiesis and Hematological Malignancies. She is an authority in treating patients with all types of leukemia and myelodysplastic syndromes, including hematopoietic cell transplants. Her research efforts are directed to the design of clinical trials that tailor therapy to the individual patient. Dr. Stock’s laboratory has focused on the identification of new biological prognostic factors in specific subsets of leukemia and on the clinical significance of molecular detection and monitoring of subclinical disease (or minimal residual disease) using quantitative molecular methods.
Dr. Uy is a Professor of Medicine in the Division of Oncology, Section of Bone Marrow Transplantation & Leukemia and Medical Director for Clinical Research in the Division of Oncology at the Washington University School of Medicine in St. Louis, MO. His research is focused on the development of new agents and treatment approaches for patients with myelodysplastic syndromes and acute leukemias. His primary research focus is on modulating tumor microenvironment interactions to improve therapy for acute leukemia. Dr. Uy is also interested in the use of next generation sequencing technologies to measure disease response in myelodsysplastic syndromes and acute myeloid leukemia.
For other articles in this issue of the Alliance E-News newsletter, see below.
-
New Alliance Committee Leadership
Alliance Leukemia Committee Co-Chairs
Alliance Symptom Intervention Vice-Chairs -
Spotlight on Alliance Trials
Alliance A082002 - Non-Small Cell Lung Cancer
Alliance A032002 - Metastatic Urothelial Cancer
Alliance A211901 - Smoking Cessation Interventions - Alliance Research Spotlight | Recap 2021 ASH Meeting
- Alliance Funding Opportunity
-
Alliance in the News
Alliance A041702 | NCI Sponsored Trial of Uproleselan in Older, Newly Diagnosed AML Patients Fit for Intensive Chemotherapy Completes Enrollment of Phase 2 Portion Ahead of Schedule
Alliance A041202 | Jennifer A. Woyach, MD, Discusses Previous Results of the A041202 Trial Examining Ibrutinib Regimens in CLL
Inaugural ASCO Plenary Series Session [AFT-39 PRO-TECT] | Digital Symptom Monitoring Using Patient-Reported Data Helps Improve Symptom Control and Physical Function of Patients During Cancer Treatment
CALGB/Alliance AML Trials 1986-2016 | AML in Younger Black AYAs Molecularly Distinct, Associated with Shorter Survival
CALGB 40603 | CALGB 40603 (Alliance): Long-Term Outcomes and Genomic Correlates of Response and Survival After Neoadjuvant Chemotherapy With or Without Carboplatin and Bevacizumab in Triple-Negative Breast Cancer
CALGB 89803 | Diet- and Lifestyle-Based Prediction Models to Estimate Cancer Recurrence and Death in Patients With Stage III Colon Cancer (CALGB 89803/Alliance)